Advertisement

Instant Oncology: Impower133

Published:December 13, 2021DOI:https://doi.org/10.1016/j.clon.2021.11.021
      The author declares no conflicts of interest.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Horn L.
        • Mansfield A.S.
        • Szczęsna A.
        • Havel L.
        • Krzakowski M.
        • Hochmair M.J.
        • et al.
        First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.
        N Engl J Med. 2018; 379: 2220-2229
        • Alexandrov L.B.
        • Nik-Zainal S.
        • Wedge D.C.
        • Aparicio S.A.
        • Behjati S.
        • Biankin A.V.
        • et al.
        Signatures of mutational processes in human cancer.
        Nature. 2013; 500: 415-421
        • Slotman B.
        • Faivre-Finn C.
        • Kramer G.
        • Rankin E.
        • Snee M.
        • Hatton M.
        • et al.
        Prophylactic cranial irradiation in extensive small-cell lung cancer.
        N Engl J Med. 2007; 357: 664-672
        • Takahashi T.
        • Yamanaka T.
        • Seto T.
        • Harada H.
        • Nokihara H.
        • Saka H.
        • et al.
        Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2017; 18: 663-671
        • Slotman B.J.
        • van Tinteren H.
        • Praag J.O.
        • Knegjens J.L.
        • El Sharouni S.Y.
        • Hatton M.
        • et al.
        Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.
        Lancet. 2015; 385: 36-42
        • Liu S.V.
        • Reck M.
        • Mansfield A.S.
        • Mok T.
        • Scherpereel A.
        • Reinmuth N.
        • et al.
        Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).
        J Clin Oncol. 2021; 39: 619-630
        • Paz-Ares L.
        • Dvorkin M.
        • Chen Y.
        • Reinmuth N.
        • Hotta K.
        • Trukhin D.
        • et al.
        Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
        Lancet. 2019; 394: 1929-1939
        • Goldman J.W.
        • Dvorkin M.
        • Chen Y.
        • Reinmuth N.
        • Hotta K.
        • Trukhin D.
        • et al.
        Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 51-65
        • Rudin C.M.
        • Awad M.M.
        • Navarro A.
        • Gottfried M.
        • Peters S.
        • Csőszi T.
        • et al.
        Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study.
        J Clin Oncol. 2020; 38: 2369-2379